President and CEO Ed McDermott talks about his his teachers, mentors and experiences over 34 years at the Ludwig Institute.
Read MoreTwo recent studies described the use of aneuploidy as a marker for likely response to immunotherapy and, separately, to identify patients with metastatic non-small cell lung cancer who might benefit from combined immunotherapy and radiotherapy.
Jedd Wolchok of Weill Cornell and Nicolas Killen of the Geneva-based law firm Borel & Barbey have joined the Board of Directors of the Ludwig Institute for Cancer Research and the LICR Fund, which manages the assets of the institute.
Read More
